Intracoronary Injection of Autologous Bone Marrow Cells in Patients With Chronic Heart Failure: Five Years Follow up

Assaf-Harofeh Medical Center8 enrolled

Overview

The study aim is to evaluate the long term outcome of intra-coronary autologous bone marrow (BM) transplantation in patients with severe ischemic cardiomyopathy without the option for revascularization.

Several studies have demonstrated the short term safety, feasibility and efficacy of cell transplantation in patients with advanced heart failure. There are no data about the long term outcome.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Ischemic Symptomatic Heart Failure

Interventions

Autologous bone marrow intracoronary infusionPROCEDURE

Percutaneous intracoronary mononuclear bone marrow cell infusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 88 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with evidence of hibernation and/or ischemia in at least 2 different myocardial segments underwent coronary angiography Exclusion Criteria: * Idiopathic or non-ischemic cardiomyopathy * Other etiology for heart failure, history of past or current disease involving the bone marrow * Patients on dialysis * Positive serologic test for HIV, hepatitis B or C or any neoplastic or terminal disease

Locations (1)

Assaf Harofeh

Ẕerifin, Israel

Outcomes

Primary Outcomes

Procedure success

Time frame: 9 months

Secondary Outcomes

Functional class improvement

Time frame: 9 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.